<DOC>
	<DOCNO>NCT02732015</DOCNO>
	<brief_summary>The goal clinical research study compare rolapitant fosaprepitant control prevent nausea and/or vomit may cause chemotherapy patient sarcoma .</brief_summary>
	<brief_title>Effects Rolapitant Nausea/Vomiting Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy ( HEC ) With Doxorubicin Ifosfamide Regimen ( AI )</brief_title>
	<detailed_description>Study Groups Study Drug Administration : There 2 part study . If participant find eligible take part study , assign either Part 1 Part 2 base join study . Each study cycle 21 day . If participant enrol Part 1 study , receive rolapitant mouth Day 1 cycle . If participant enrol Part 2 study , randomly assign ( flip coin ) 1 2 study group learn study drug receive . This do one know one group well , , bad . - If participant Group A , receive rolapitant mouth Day 1 cycle . - If participant Group B , receive fosaprepitant vein 30 minute Day 1 cycle . Depending participant responds drug , may also receive fosaprepitant Days 1 4 Cycles 2 beyond . Participant study staff know group participant assign . Both group also receive additional supportive drug ( dexamethasone ondansetron ) chemotherapy , every day 5 day , help prevent nausea vomit . Participant may ask study staff information drug give risk . Participant also receive chemotherapy prescribe doctor . Participant sign separate consent form chemotherapy describe treatment detail , along risk . Before chemotherapy cycle , participant give study diary . Each day , participant record side effect may . Participant bring study diary every study visit . Study Visits : Within 1 week cycle : - Participant physical exam . - Participant fill questionnaire screening . - Blood ( 1 teaspoon ) drawn routine test . Participant blood draw repeat 2 time week Cycle 1 . Participant may choose blood draw perform local lab clinic closer home . The result blood test send study doctor review . This option discuss participant . Length Study : Participant may receive 6 cycle chemotherapy/study drug . Participant longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Patient 's participation study complete end-of-study visit . End-of-Study Visit : About 3 week last dose rolapitant/fosaprepitant : - Participant physical exam . - Participant fill questionnaire screening . This investigational study . Both fosaprepitant rolapitant FDA approve commercially available prevention nausea vomit may cause chemotherapy . It consider investigational compare 2 standard treatment one another learn one effective . The study doctor explain study drug design work . Up 91 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<mesh_term>8- ( ( 1- ( 3,5-bis ( trifluoromethyl ) phenyl ) ethoxy ) methyl ) -8-phenyl-1,7-diazaspiro ( 4,5 ) decan-2-one</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>1 . Patients sarcoma locally advance , high risk relapse metastatic treatment doxorubicin plus ifosfamide ( AI ) AI vincristine ( VAI ) indicate . 2 . Must 18 65 year age . 3 . Patient must estimate life expectancy &gt; = 4 month opinion investigator . 4 . Male Females child bear potential must use acceptable method birth control include oral contraceptive , spermicide either condom , diaphragm cervical cap , u intrauterine device ( IUD ) abstinence . ( 1 ) Female patient must negative pregnancy test Screening ; ( 2 ) Female patient childbearing potential must agree use acceptable method birth control ( exclude hormonal birth control method ) 72 hour prior admission continue use study least 30 day final dose ; ( 3 ) Male patient must agree use acceptable form birth control study Day 1 least 30 day final dose . 5 . Adequate hematologic ( ANC &gt; 1500/mm^3 , platelet count &gt; 100,000/mm^3 ) , renal ( serum creatinine &lt; 1.5mg/dL ) , hepatic [ serum bilirubin count &lt; 1.5 x upper limit normal ( ULN ) SGOT SGPT &lt; 2.5 x ULN , subject know liver metastasis &lt; 5 x ULN ] function . 6 . Karnofsky Performance Status &gt; 60 % . 7 . Signed informed consent form . 8 . Patients require read understand English comply protocol requirement . 1 . Any current treatment , medical history , uncontrolled condition , malignancy , ( e.g. , alcoholism sign alcohol abuse , seizure disorder , medical psychiatric condition ) , opinion investigator , would confound result study pose unwarranted risk administer study drug subject 2 . Patient known hypersensitivity administration prescribe oral intravenous study medication metabolite , include limited , history hypersensitivity drug component , severe renal impairment , severe bone marrow suppression , systemic infection 3 . Patient woman positive urine serum pregnancy test within 3 day prior study drug administration , breastfeed , plan conceive child within project duration study treatment 4 . Patient take antiemetic agent within last 48 hour prior start treatment study drug : ( 1 ) . 5HT3 antagonist ( ondansetron , granisetron , dolasetron , tropisetron , etc. ) . Palonosetron permit within 7 day prior administration investigational product ; ( 2 ) . Phenothiazines ( prochlorperazine , fluphenazine , perphenazine , thiethylperazine , chlorpromazine , etc . ) ; ( 3 ) . Benzamides ( metoclopramide , alizapride , etc . ) ; ( 4 ) . Domperidone ; ( 5 ) Cannabinoids ; ( 6 ) NK1 antagonist ( aprepitant ) ; ( 7 ) Benzodiazepines ( lorazepam , alprazolam , etc ) ; ( 8 ) herbal medication preparation dos design ameliorate nausea emesis 5 . Patient receive systemic corticosteroid sedative antihistamine ( dimenhydrinate , diphenhydramine , etc . ) within 72 hour Day 1 study except premedication chemotherapy ( e.g. , taxanes ) . Subjects receive inhaled steroid respiratory condition topical steroid skin disorder enrol 6 . Patient symptomatic primary metastatic CNS disease 7 . Patient ongoing vomiting , retch , dry heave , clinically significant nausea cause etiology , symptom within 24 hour prior start Day 1 study intervention , history anticipatory nausea vomit 8 . Patient must dose test drug blind study drug another investigational study within 30 day 5 halflives biologic activity test drug , whichever longer , time first study dose 9 . Patient participate investigational agent FDAapproved . 10 . Patient uncontrolled angina , congestive heart failure ( New York Heart Association &gt; class II know ejection fraction &lt; 40 % ) , uncontrolled cardiac arrhythmia hypertension , acute myocardial infarction within 3 month . 11 . Prior surgery radiotherapy ( RT ) within 2 week study entry . 12 . Psychological , social , familial , geographical reason would prevent schedule visit followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Sarcoma</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>High risk relapse</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Surveys</keyword>
	<keyword>Rolapitant</keyword>
	<keyword>Fosaprepitant</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Ondansetron</keyword>
	<keyword>Zofran</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Adriamycin PFS</keyword>
	<keyword>Adriamycin RDF</keyword>
	<keyword>Rubex</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
	<keyword>Ifosfamide</keyword>
	<keyword>Ifex</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
</DOC>